Shek Law   Assistant Professor of Pharmacology in Radiology

Nanomedicine for drug delivery

Chemotherapy is the first line treatment for many cancers. Unfortunately, it is known to induce many adverse effects, including nausea, vomiting, and peripheral neurotoxicity. The advance in nanomedicine facilitates many novel approaches to deliver chemotherapy through active and passive targeting. Our group is interested in a new type of two-dimensional nanomaterial, such as a peptide nanofiber (PF) that is biocompatible, able to penetrate inside a tumor, and has a short circulation time to avoid non-specific in vivo distribution with a high tumor uptake.

Mitochondrial targeting agent

The treatment of any recurrent, resistant, and metastatic cancer remains a major challenge. Many patients who respond to an initial chemotherapy may result in acquiring drug resistance in a short period of time. The co-exist of multiple drug resistance (MDR) make it impracticable to use every drug combinations in a clinical setting. Further, polypharmacy is prompt to create additional side effects. We are focused on the research on personlaized approaches to eradicate MDR breast cancer using cytotoxic agents that selectively target the tumoral mitochondria.nbsp;

Optical imaging

Optical imaging has become an emerging tool for biomedical research. A high background from the tissue often limits fluorescence imaging technique. The long-term goal of our laboratory is to develop state-of-art contrast agents for improving the sensitivity and capability for optical imaging, using new long-emitting FRET and BRET nanoparticles. These technologies can be applied to detect specific disease biomarkers as well as to image guided drug delivery.

Publications

Sort by

Selected publications

Research

Sort by

Grants awarded

Background

Contact

full name

  • Dr. Shek Law,

primary email

  • sbl2004@med.cornell.edu

Other

Primary Affiliation

  • Weill Cornell Medical College, Cornell University